Psychedelic Psychotherapy

Dr. McLane is the founder and director of SoundMind Project and SoundMind Center of Philadelphia, which is set to be one of the first psychedelic therapy centers of its kind. She is part of the highly selective training cohort with MAPS in order to be able to administer MDMA (ecstasy) as part of psychotherapy. Her center will likely be able to offer MDMA as an adjunct to therapy in 2024 or 2025. See more about this therapy here.

Dr. McLane is also excited about the prospect of psilocybin (aka magic mushrooms) being available in the coming years, as there are decriminalization and legalization efforts happening throughout the country. Oregon recently voted to make psilocybin legal for therapeutic purposes, and it will likely take 2 or more years before that is fully implemented. We hope the rest of the country follows suit.

If you live in the Philadelphia region and are looking for psychedelic psychotherapy:

  • At Soundmind Dr. McLane and her team conduct Ketamine-assisted psychotherapy (KAP), as this is the only legal psychedelic currently available in our region. Ketamine-assisted psychotherapy involves taking a ketamine lozenge (cough drop) and doing simultaneous psychotherapy. It is effective for depression and some forms of PTSD.

  • If you are interested in signing up for Ketamine-assisted psychotherapy or learning about other psychedelic therapy offerings see www.soundmind.center for more information.

  • Here is more information about KAP insurance reimbursement and fees.

Frequently Asked Questions

  • What about underground use of psychedelics? Is that a good idea?

    • We only operate on the legal side of psychedelic therapy, and although there are people out there who offer underground therapy before it becomes legal, we do not practice this nor can we recommend those who do. If you choose to use psychedelics on your own and need someone to talk to about your experiences, this is called ‘psychedelic integration therapy’ and we can offer this in the form of psychotherapy.